Stage 4 / metastatic lung cancer, explained simply

Stage 4 lung cancer, also written as stage IV, means the cancer has spread beyond the lung where it began. It is often called metastatic or advanced lung cancer. The stage describes how far the cancer has travelled — for example to the other lung, the lining around the lung, or distant organs such as the brain, liver, or bone — and not how long someone has to live. Stage 4 is usually divided into 4A, where the spread is more limited, and 4B, where there are several deposits in distant organs. Knowing the stage is only the start; the cell type and the tumour's biomarkers matter just as much in deciding treatment.

Yes. When doctors say lung cancer is metastatic, they mean it has spread from where it started to another part of the body, which is exactly what stage 4 describes. "Metastasis" is simply the medical word for cancer that has spread. So stage 4 lung cancer and metastatic lung cancer mean the same thing. There is a separate situation where a cancer that began in another organ spreads to the lungs — that is called secondary lung cancer, and it is treated as the original cancer type. Confirming where the cancer truly started, usually with a biopsy, is the first step in shaping the right plan.

By stage 4, symptoms can come both from the lung and from wherever the cancer has spread. From the lung, common signs include a cough that will not settle, breathlessness, chest pain, or coughing up blood. Whole-body signs such as tiredness, loss of appetite, and unexplained weight loss are common. If the cancer has reached the bones it may cause persistent pain; spread to the brain can cause headaches, vision changes, or confusion; and spread to the liver can cause upper-tummy discomfort or jaundice. Some people feel surprisingly well. These symptoms overlap with many other conditions, so proper testing is what tells them apart.

Diagnosis usually begins with imaging — a CT scan, often a whole-body PET-CT, and sometimes an MRI of the brain — to map where the cancer has spread and confirm that it is stage 4. Scans guide the stage but cannot identify the cell type on their own, so a biopsy is taken from the lung tumour or another accessible site and examined under a microscope. This confirms whether it is non-small cell or small cell lung cancer. The tissue is then tested for biomarkers such as EGFR, ALK, ROS1, and PD-L1. At CION, the full picture is reviewed by a multidisciplinary tumour board before a plan is agreed.

Treatment is chosen by the cell type, the biomarkers, and how widely the cancer has spread, and it often combines more than one approach. Options include targeted therapy matched to a change such as EGFR, ALK, or ROS1; immunotherapy, sometimes with chemotherapy; chemotherapy on its own; and radiation to ease symptoms or treat spread to the brain or bone. For a few people with very limited spread, called oligometastatic disease, more focused treatment of the few sites may be possible. Supportive and palliative care runs alongside from the start to control symptoms and protect quality of life. At CION, every plan is agreed by a tumour board so it reflects the combined judgement of medical, surgical, and radiation oncologists.

Biomarker, or molecular, testing examines the biopsy tissue for specific gene changes and proteins. In stage 4 lung cancer, certain changes — such as EGFR, ALK, ROS1, and others — can be matched to targeted drugs that act on those exact changes, and PD-L1 levels help guide whether immunotherapy may help. This means treatment can be tailored rather than one-size-fits-all, and it sometimes opens up options that the stage alone would not reveal. Because these results can meaningfully change the recommended treatment and the outlook, biomarker testing is now a routine and important part of the work-up for stage 4 disease, and it is worth confirming it has been done.

Yes. Stage 4 disease is serious, but it is not the end of the road. The aim of treatment shifts towards controlling the cancer throughout the body, easing symptoms, and protecting quality of life, often for a long time. Modern treatments — targeted therapy, immunotherapy, chemotherapy, and precise radiation — can do this effectively for many people, and the options have grown considerably in recent years. For a small number of people with very limited spread, called oligometastatic disease, more focused treatment of the few sites may be possible. The right approach depends on the cell type, biomarkers, and overall health, which is why each plan is individualised rather than decided by the stage number alone.

There is no single survival figure that applies to everyone with stage 4 lung cancer, and we deliberately avoid quoting a percentage, because survival statistics describe large groups from the past and cannot predict one person's journey. Outlook depends on the cell type, the biomarkers found, how widely the cancer has spread, overall health and fitness, and how the cancer responds to treatment. What has changed is that targeted therapy and immunotherapy have meaningfully improved what is possible for some people compared with a decade ago. For an honest, individual picture, the only reliable answer comes from your own team after they review your cancer type, biomarkers, and spread together.

No. "Stage 4" and "terminal" are not the same thing. Stage 4 describes how far the cancer has spread, while terminal describes a phase in which the cancer can no longer be controlled and care has shifted fully to comfort. Many people with stage 4 lung cancer are not in that phase — their cancer is being actively treated and held in check, sometimes for years, especially when a treatable biomarker is found. Outcomes vary widely from person to person, and the idea that a stage 4 diagnosis means there is nothing to be done is out of date. You can read more about whether stage 4 lung cancer is always terminal, and discuss your own situation with a specialist.

Seeking a second opinion is reasonable and common, especially for a diagnosis as significant as stage 4 lung cancer. A second opinion can confirm the cell type, check that full biomarker testing has been done, and make sure all suitable treatment options have been considered. It does not delay care in most situations, and it can bring real peace of mind. At CION, the first 45-minute consultation is free and doctor-led, and includes a written second opinion. You are under no obligation to start treatment — the aim is simply to give you a clear, honest picture so you can make a decision you feel settled with.